Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/3630
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanchez-Garrido, Miguel A.-
dc.contributor.authorTena-Sempere, Manuel-
dc.date.accessioned2022-05-11T12:13:40Z-
dc.date.available2022-05-11T12:13:40Z-
dc.date.issued2020-02-05-
dc.identifier.citationSanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020 May;35:100937es_ES
dc.identifier.issn2212-8778 (Online)es_ES
dc.identifier.otherPMC7115104es_ES
dc.identifier.urihttp://hdl.handle.net/10668/3630-
dc.description.abstractBackground: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive age women. Although its cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, PCOS women often display also notable metabolic comorbidities. An array of pathogenic mechanisms have been implicated in the etiology of this heterogeneous endocrine disorder; hyperandrogenism at various developmental periods is proposed as a major driver of the metabolic and reproductive perturbations associated with PCOS. However, the current understanding of the pathophysiology of PCOS-associated metabolic disease is incomplete, and therapeutic strategies used to manage this syndrome's metabolic complications remain limited. Scope of review:This study is a systematic review of the potential etiopathogenic mechanisms of metabolic dysfunction frequently associated with PCOS, with special emphasis on the metabolic impact of androgen excess on different metabolic tissues and the brain. We also briefly summarize the therapeutic approaches currently available to manage metabolic perturbations linked to PCOS, highlighting current weaknesses and future directions. Major conclusions:Androgen excess plays a prominent role in the development of metabolic disturbances associated with PCOS, with a discernible impact on key peripheral metabolic tissues, including the adipose, liver, pancreas, and muscle, and very prominently the brain, contributing to the constellation of metabolic complications of PCOS, from obesity to insulin resistance. However, the current understanding of the pathogenic roles of hyperandrogenism in metabolic dysfunction of PCOS and the underlying mechanisms remain largely incomplete. In addition, the development of more efficient, even personalized therapeutic strategies for the metabolic management of PCOS patients persists as an unmet need that will certainly benefit from a better comprehension of the molecular basis of this heterogeneous syndrome.es_ES
dc.description.sponsorshipResearch activities at the authors' laboratory related to the contents of this work were funded by grants BFU2017-83934-P (to MT-S; Ministry of Economy and Competitiveness, Spain, co-funded with EU funds from the FEDER Program), project PIE14-00005 (to MT-S; Flexi-Met, Carlos III Health Institute, Ministry of Health, Spain), and project PI-0358-2018-FIB (to MAS-G; FIBICO). CIBER is an initiative of the Carlos III Health Institute (Ministry of Health, Spain).es_ES
dc.format.extent16 p.es_ES
dc.language.isoenes_ES
dc.publisherElsevieres_ES
dc.relation.ispartofMolecular Metabolismes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPCOSes_ES
dc.subjectAndrogen excesses_ES
dc.subjectInsulin resistancees_ES
dc.subjectObesityes_ES
dc.subjectPoly-agonistses_ES
dc.subjectGLP-1es_ES
dc.subjectSíndrome del ovario poliquísticoes_ES
dc.subjectResistencia a la insulinaes_ES
dc.subjectObesidades_ES
dc.subjectPéptido 1 similar al glucagónes_ES
dc.subject.meshMedical Subject Headings::Anatomy::Tissues::Connective Tissue::Adipose Tissuees_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Androgenses_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animalses_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Bariatrics::Bariatric Surgeryes_ES
dc.subject.meshMedical Subject Headings::Check Tags::Femalees_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Diseases::Endocrine System Diseases::Gonadal Disorders::Disorders of Sex Development::Adrenogenital Syndrome::Hyperandrogenismes_ES
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome Xes_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Micees_ES
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesityes_ES
dc.subject.meshMedical Subject Headings::Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Genital Diseases, Female::Adnexal Diseases::Ovarian Diseases::Ovarian Cysts::Polycystic Ovary Syndromees_ES
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Insulin Resistancees_ES
dc.titleMetabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.versionYeses_ES
dc.identifier.pmid32244180es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.identifier.doi10.1016/j.molmet.2020.01.001es_ES
dc.type.versioninfo:eu-repo/semantics/publishedes_ES
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S221287782030003Xes_ES
dc.contributor.authoraffiliation[Sanchez-Garrido,MA; Tena-Sempere,M] Instituto Maimónides de Investigación Biomédica de Cordoba (IMIBIC), Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] Department of Cell Biology, Physiology, and Immunology, University of Cordoba, Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] Hospital Universitario Reina Sofia, Cordoba, Spain. [Sanchez-Garrido,MA; Tena-Sempere,M] CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III Cordoba, Spain. [Tena-Sempere,M] FiDiPro Program, Institute of Biomedicine, University of Turku, FIN-20520 Turku, Finland.es_ES
dc.type.subtypeRevisiónes_ES
Appears in Collections:01- Artículos - Hospital Reina Sofía
01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba

Files in This Item:
File Description SizeFormat 
SanchezGarrido_MetabolicDysfunction.pdfRevisión sistemática1,23 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons